Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company formed in 2013 and listed on the ASX in 2018 with a revolutionary idea – that exosomes could replace stem cells and become a new generation of medicine.

Currently, Exopharm has grown to become a global leader in the commercialisation of exosome-based medicines.

The company uses exosomes (extracellular vesicles (EVs)) from cells to generate a new class of transformative medicines.

From day one, Exopharm has focused on addressing the existing limitations in exosome purification processes to unlock the potential of EVs.

Various Exopharm EV products harness the powerful natural ability of EVs to efficiently target cells and transfer selected materials into cells and across barriers.

In 2018 the company became a listed company on the ASX  and in 2019 ran its first clinical trial, with its second clinical trial is due to report in early CY 2021.

Since its formation, Exopharm has grown to be a 41-person team based at the Baker Institute in Melbourne.

Shareholder update April 2021


Ian Dixon, Managing Director & Founder

Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.

He is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.

Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.

Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).

read more

Chris Baldwin, Deputy CEO & Chief Commercial Officer

Dr Chris Baldwin received his PhD in Chemical Engineering from the University of Cambridge, while matriculated at Trinity College. Chris joined Exopharm in November 2019, bringing a wide range of global commercial experience to the company.

Most recently, Chris was responsible for Haemonetics’ largest and most profitable business unit across Asia Pacific, with P&L responsibilities from Taiwan to Pakistan. Previously responsible for all sales and marketing in Southeast Asia, Chris provided strategy leadership across Asia Pacific, including China.

Chris’ strategic focus and approach to management comes from his time at McKinsey and Company, where he served banking, pharmaceutical and NGO clients.

Healthcare became the focus of Chris’ career at New York Blood Center, where he was Executive Director for 8 years and responsible for the blood supply across the greater New York metropolitan area.

read more

Gregor Lichtfuss, Chief Operating Officer & Co-Founder

Dr Gregor Lichtfuss holds a PhD in Medicine / clinical immunology from Monash University, a Master of Science in International Health from Humboldt University Berlin and a Diploma in Biologie (Virology and Genetics) from Humboldt University Berlin. Gregor is a co-inventor of the LEAP Technology.

Gregor brings significant entrepreneurial experience in creating biotechnology startups and health solutions, in-depth experience and knowledge in molecular science and technology as well as an understanding of international health systems and early-stage drug development.

Gregor worked in early-stage research commercialisation at the Spinnovator, the startup creation hub managed by Ascenion GmbH, where he was instrumental in laying the business foundation for Cardior Pharmaceuticals GmbH, a biotechnology company developing novel treatments for heart failure. He has also worked as a consultant to Brandon Capital Partners in Melbourne.

read more

Alison Cook, Director of Manufacturing & Development

Alison Cook has more than 30 years of management and leadership experience across the biopharmaceutical, diagnostic and health service sectors. She has held senior Operations Management and General Management roles across several divisions of CSL Ltd during the 13 years she was with the company, including flu vaccine and antivenom manufacture. Executive roles as COO and then CEO of Genetic Technologies Ltd and consulting in manufacturing operations, strategy and quality to biotechnology companies across Asia Pacific with Centre for Biopharmaceutical Excellence (CBE) have extended her experience.

Alison is Director at Centre for Biopharmaceutical Excellence Pty Ltd and Non-Executive Director at McPherson Ltd.

read more